General situation of Yunnan watson biological Technology Co., Ltd.

At present, there are more than 580 employees, including more than 1 10 professionals engaged in research and development. Since the first independent innovative vaccine product was put into production in September 2007, the company's operating income and profits have doubled year after year. At present, the company is the first enterprise in China with two bacterial polysaccharide-protein conjugate vaccine products listed. The company has advanced new vaccine research and development center and pilot base in Kunming National High-tech Zone. There are modern vaccine production bases in Yuxi High-tech Zone and China Medical City in Taizhou, Jiangsu. Its marketing network covers 29 provinces and cities and more than 2,000 districts and counties in China.